BioInfra Co., Ltd. (KOSDAQ:199730)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,580.00
-54.00 (-3.30%)
At close: Jul 20, 2026
Market Cap8.07B -70.1%
Revenue (ttm)23.21B -4.3%
Net Income-9.89B
EPS-2,031.96
Shares Out 4.86M
PE Ration/a
Forward PEn/a
Dividend300.00 (18.36%)
Ex-Dividend DateDec 29, 2025
Volume18,849
Open1,595.00
Previous Close1,634.00
Day's Range1,540.00 - 1,687.00
52-Week Range1,500.00 - 6,330.00
Beta0.37
Analystsn/a
Price Targetn/a
Earnings Daten/a

About BioInfra

BioInfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials. The company provides clinical, which undertakes clinical trials for new drug development approval (Phase I-III) and late clinical trials; immunoassay, which performs pharmacokinetic, toxicokinetic, and biomarker analysis of polymer biopharmaceuticals; and testing and inspection, which provides finished drug product quality inspection, comparative dissolution testing, and long-term stability testing. It also specializes in bioequivalence testing of gener... [Read more]

Industry Commercial Physical and Biological Research
Founded 2007
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 199730
Full Company Profile

Financial Performance

In 2025, BioInfra's revenue was 23.15 billion, a decrease of -2.87% compared to the previous year's 23.83 billion. Losses were -9.13 billion, 129.7% more than in 2024.

Financial Statements